News

EHA 2025: AstraZeneca’s surovatamig is potential next-gen BiTE for R/R B-ALL
This trial evaluated the safety, tolerability, pharmacodynamics, pharmacokinetics and clinical activity of AstraZeneca’s ...
The Pharma Letter3h
AstraZeneca’s Ultomiris shows strong OS in HSCT TMA
Initial results from the ALXN1210-TMA-314 Phase III trial showed that UK pharma major AstraZeneca’s Ultomiris (ravulizumab) ...
Fierce Biotech3d
AstraZeneca pens $5.3B pact to use CSPC's AI platform to develop oral drugs for chronic diseases
CSPC will use its artificial-intelligence-driven, dual-engine efficient drug discovery platform to analyze the binding ...
AstraZeneca: Fascinating Company With Lofty Ambitions - Just Not A Buy Yet
AstraZeneca targets $80bn revenue by 2030, driven by oncology and new drugs, but faces patent risks and tough competition.
AstraZeneca Unit Owes $180 Million-Plus in Syntimmune Case (1)
An AstraZeneca Plc affiliate suffered a greater than $180 million court loss Wednesday over its lackluster efforts to ...
KSL9d
AstraZeneca sues Utah attorney general over new Utah drug price law
The pharmaceutical drug company AstraZeneca filed a lawsuit against the Utah attorney general claiming Utah's new law on ...
AstraZeneca’s ENHERTU Enters Pivotal Phase 3 Trial for Endometrial Cancer
AstraZeneca (NASDAQ:AZN) is one of the 8 Best Inexpensive Stocks to Buy Right Now. On June 9, the first patient was dosed by ...
BioPharma Dive2d
AstraZeneca forms an AI deal in China; Third Harmonic advances liquidation plans
AstraZeneca could spend up to $5.3 billion in a deal to develop oral medicines with CSPC Pharmaceutical. Elsewhere, Insmed ...